Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients

Autor:	Mark Stroh, Vanessa Huels, Rachel Humphrey, Matthias Will, Beiyao Zheng, Joshua F. Apgar, Bjorn L. Millard, Nancy Zheng, Hong Lu, Jennifer Richardson, Serwer Laura Patterson, Chihunt Wong
Rok vydání:	2018
Předmět:	Cancer Research biology business.industry Anti pd 1 Cancer Pharmacology Prodrug medicine.disease Programmed cell death ligand 1 Oncology Pharmacokinetics biology.protein Medicine Antibody business
Zdroj:	Journal of Clinical Oncology. 36:e14558-e14558
ISSN:	1527-7755 0732-183X
Popis:	e14558Background: CX-072 is a protease-activatable antibody prodrug directed against programmed cell death ligand 1 (PD-L1). Probody therapeutics (Pb-Txs) are designed to be preferentially activate...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a0828e978c1a3ac9d38d9726722711db https://doi.org/10.1200/jco.2018.36.15_suppl.e14558 Zobrazit plný text záznamu